RxDoctor Payments Data

Emma Cotton

Medical · Brockton, MANPI 1851918916

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.4% of the total across 250 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 23.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,670 and has fallen 52.5% since, to $793 in 2025. Among medical clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,490in general payments, 2019–2025

Across 250 payments — averaging $21.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Astellas Pharma US Inc$557
  • Pfizer$529
  • Dentsply IH AB$433
  • Myovant Sciences Inc.$408
  • Sumitomo Pharma America, Inc.$386
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$5,23595%
  • Education$2555%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,490 in reported general payments places this provider in the 95th percentile of 421 medical providers in Massachusetts.

See all medical providers in Massachusetts

Most prescribed under Part D

DrugClaimsCost to plans & patients
EstringEstradiol73$38,288
IbsrelaTenapanor Hcl15$37,350
PremarinEstrogens, Conjugated54$25,045
Estradiol223$14,797
GemtesaVibegron15$12,565
MyrbetriqMirabegron21$10,779
Estradiol (Once Weekly)Estradiol31$3,409
Estradiol (Twice Weekly)Estradiol15$1,596
Fosfomycin Tromethamine12$1,241
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst39$369
Metronidazole26$354
Triamcinolone Acetonide55$272
Levothyroxine Sodium15$223
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav25$161
Ciprofloxacin Hcl37$132

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEstring, Premarin$529$63,333127 claims
Ardelyx, Inc.Ibsrela$211$37,35015 claims
Sumitomo Pharma America, Inc.Gemtesa$386$12,56515 claims
Astellas Pharma US IncMyrbetriq$557$10,77921 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 421 medical providers in Massachusetts.

Other medical in Brockton

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →